Tiger Brokers

Zai Lab's Lung Cancer Drug Achieves Promising Response Rate in Phase 1b Trial; Shares up 4%

MT Newswires Live
Oct 26

Zai Lab (HKG:9688) said patients responded well to its lung cancer treatment, Zoci, in combination with other drugs during a global phase 1b study, according to a Friday bourse filing.

The biopharma company said patients with extensive-stage small cell lung cancer, who received Zoci plus atezolizumab achieved a confirmed objective response rate (ORR) of 81.8%, while the ORR was 92.3% in those who received the drug with atezolizumab and carboplatin.

Zai Lab said it will present the findings from the study at the European Society for Medical Oncology Congress 2026 in Madrid, Spain, and plans to initiate a global phase 3 trial of its drug along with an immuno-oncology regimen by the end of the year.

Shares were up nearly 4% in Monday's late-morning trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10